Mesoblast Limited

Announcements / Press Releases

2011-December-9	Form 604 Notice of Change of Interests of Sub Holder (in PDF)
2011-November-24	Results of Meeting (in PDF)
2011-November-24	Corporate Strategy Key to Mesoblast's Success (in PDF)
2011-November-24	A Year of Transformation - Address by Mesoblast Chairman Mr Brian Jamieson - 2011 Annual General Meeting (in PDF)
2011-November-22	Positive Outcome from FDA Meeting for Diabetes Program (in PDF)
2011-November-15	Positive Heart Failure Trial Results Presented to AHA (in PDF)
2011-November-10	Positive Results Using Adult Stem Cells for Type 2 Diabetes (in PDF)
2011-October-31	Appendix 4C - Quarterly (in PDF)
2011-October-28	Response to ASX Price Query Letter (in PDF)
2011-October-24	Notice of Annual General Meeting/Proxy Form (in PDF)
2011-October-24	Clearance for First Phase 2 Clinical Trial for Eye Diseases (in PDF)
2011-October-20	Licensing Executives Society (U.S.A. and Canada) 2011 Deals of Distinction™ Award for Life Sciences to Mesoblast, Cephalon Alliance (in PDF)
2011-September-27	MSB and Lonza Form Strategic Global Manufacturing Alliance (in PDF)
2011-September-5	First European Trial for Heart Attack Treatment Cleared (in PDF)
2011-August-31	Financial Report for the Year Ended 30 June 2011 (in PDF)
2011-August-24	Mesoblast in Position of Considerable Strength (in PDF)
2011-August-24	Appendix 4E - Preliminary Final Report Year Ending on 30 June 2011 (in PDF)
2011-August-22	First Minimally Invasive Procedure for Lumbar Disc Repair (in PDF)
2011-August-21	Mesoblast Limited Results Briefing (in PDF)
2011-August-15	Heart Failure Trial Selected for AHA Special Session (in PDF)
2011-August-1	Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
2011-July-7	FDA Clearance for Phase 3 Bone Marrow Transplant Trial (in PDF)
2011-July-6	Appendix 3B (in PDF)
2011-July-4	Amended Change of Director's Interest Notice - Michael Spooner (in PDF)
2011-June-29	FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease (in PDF)
2011-June-14	Key Product Franchises Featured at Nomura Asia Equity Forum (in PDF)
2011-June-9	Phase 2 Clinical Trial Results Show that Revascor™ Increases Blood Supply to Damaged Heart Muscle (in PDF)
2011-June-6	MSB to Present at Goldman Sachs Global Healthcare Conference (in PDF)
2011-May-24	Key USA Patents Increase Commercial Rights and Indications (in PDF)
2011-May-2	Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
2011-April-18	Mesoblast Included in S&P/ASX 200 Index (in PDF)
2011-April-11	Appendix 3B (in PDF)
2011-April-7	Mesoblast Update on Valeant Proposal to Cephalon (in PDF)
2011-March-31	Mesoblast Statement on Valeant Proposal to Cephalon (in PDF)
2011-March-17	Mesoblast CEO Named BioSpectrum Asia Person of the Year 2011 (in PDF)
2011-March-11	Appendix 3B (in PDF)
2011-February-28	Financial Report for the Half-Year Ended 31 December 2010 (in PDF)
2011-February-28	Mesoblast Half-Year Results, Strong Financial Position Underpins Company's Ability to Deliver in Increased Value from Broadened Range of Stem Cell Therapeutics (in PDF)
2011-February-28	Appendix 4D - Half Year Report for the Six Months to 31 December 2010 (in PDF)
2011-February-14	Cleansing Notice under Section 708A (in PDF)
2011-February-14	Mesoblast Issues New Equity to Cephalon, Receives Further Cash Injection (in PDF)
2011-February-11	Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities and Agreement (in PDF)
2011-February-11	Section 708AA Notice - Cleansing Statement (in PDF)
2011-February-9	Results of Extraordinary General Meeting (in PDF)
2011-February-9	Address by Mesoblast Chairman Brian Jamieson at Extraordinary General Meeting (in PDF)
2011-January-31	Mesoblast Reports Strong Cash Position after Angioblast Acquisition & Appendix 4C (in PDF)
2011-January-12	Response to ASX Price Query (in PDF)
2011-January-12	Mesoblast - Cephalon Alliance Highlighted at JP Morgan Healthcare Conference (in PDF)
2011-January-10	Interim Results from Mesoblast's Phase 2 Heart Failure Trial Shows "Off-The- Shelf" Proprietary Adult Stem Cell Product Revascor™ Reduces Cardiac Events, Mortality, and Hospitalization (in PDF)
2011-January-7	Notice of Extraordinary General Meeting/Proxy Form (in PDF)
2012	2012 Announcements / Press Releases
2010	2010 Announcements / Press Releases
2009	2009 Announcements / Press Releases
2008	2008 Announcements / Press Releases
2007	2007 Announcements / Press Releases